US Stock MarketDetailed Quotes

MLYS Mineralys Therapeutics

Watchlist
  • 13.110
  • +0.590+4.71%
Close Nov 27 16:00 ET
  • 13.663
  • +0.553+4.21%
Post 20:01 ET
652.47MMarket Cap-4256P/E (TTM)

Mineralys Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Mineralys Therapeutics Q3 2024 Earnings Date

Currency：USDNov 11, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
-0.82
-1.13
-0.31
Miss Est.
-44.74%
-98.25%
-36.99%
Analyst Rating
Strong Buy

Nov 14, 2024

Mineralys Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 11, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 11, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Mineralys Therapeutics Earnings Reports

  • Mineralys Therapeutics | 8-K: Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Nov 12 09:45 ET

  • Mineralys Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 12 09:32 ET

  • Mineralys Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 13 16:15 ET

  • Mineralys Therapeutics | 8-K: Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    Aug 13 16:12 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 14, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data